Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Niina MatikainenSanni SöderlundElias BjörnsonKirsi PietiläinenAntti HakkarainenNina LundbomMarja-Riitta TaskinenJan BorénPublished in: Diabetes, obesity & metabolism (2018)
Intervention with liraglutide for 16 weeks produces multiple improvements in cardiometabolic risk factors that were not seen in the placebo group, despite similar weight loss. Of particular importance was a marked reduction in postprandial atherogenic remnant particles. The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
Keyphrases
- risk factors
- type diabetes
- weight loss
- end stage renal disease
- double blind
- randomized controlled trial
- newly diagnosed
- poor prognosis
- bariatric surgery
- chronic kidney disease
- peritoneal dialysis
- phase iii
- cardiovascular disease
- open label
- clinical trial
- prognostic factors
- transcription factor
- glycemic control
- adipose tissue
- metabolic syndrome
- fatty acid
- combination therapy
- long non coding rna
- low density lipoprotein